ARS Pharmaceuticals launches neffyinSchools program

ARS Pharmaceuticals (SPRY) announced the launch of the neffyinSchools program. neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons of neffy 2 mg for use in emergency situations at no cost to the school via the School Health Corp. SHConnect platform. neffy 2 mg is approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. Participating schools will be eligible to receive replacement doses when the product is used or expires.